Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963621879> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W1963621879 endingPage "1502" @default.
- W1963621879 startingPage "1499" @default.
- W1963621879 abstract "The concept that drugs that prolong ventricular repolarization, and hence refractoriness, might be effective antiarrhythmics was first advanced over 25 years ago.1 Agents such as quinidine, sotalol, and amiodarone all prolong refractory periods in cardiac tissue at least partially through this mechanism, often termed a “class III” action. However, since these compounds also exert other important pharmacological actions, such as conduction slowing (by depression of sodium current or other mechanisms) or antiadrenergic effects, it has not been possible to establish that action potential prolongation is in fact antiarrhythmic in human subjects. The development of drugs whose sole pharmacological action is to prolong the cardiac action potential has now provided a tool to address this question, and indeed small clinical trials testing these agents do indicate antiarrhythmic activity.2 3 In this issue of Circulation , Stambler and colleagues4 report the results of a large, placebo-controlled, blinded trial of ibutilide, a “pure” action potential–prolonging agent, in patients with atrial fibrillation and flutter. The demonstration that ibutilide infusion can terminate atrial fibrillation or flutter was pivotal in the recent decision by the Food and Drug Administration (FDA) to approve marketing of the drug for this indication. Thus, ibutilide is the first of the “pure” action potential–prolonging agents to be available to practicing physicians.The patients reported by Stambler and colleagues represent a rather typical group of patients for whom conversion to sinus rhythm might be contemplated: 75% had a history of heart disease other than atrial fibrillation or flutter, 83% had an enlarged left atrium, 55% had depressed left ventricular systolic function, and 71% had valvular heart disease. Duration of arrhythmia and extent of underlying heart disease are known to exert a profound impact on the outcome of therapy for these arrhythmias: Only patients who had atrial fibrillation or flutter …" @default.
- W1963621879 created "2016-06-24" @default.
- W1963621879 creator A5058141203 @default.
- W1963621879 date "1996-10-01" @default.
- W1963621879 modified "2023-09-23" @default.
- W1963621879 title "Ibutilide and the Treatment of Atrial Arrhythmias" @default.
- W1963621879 cites W1763503342 @default.
- W1963621879 cites W1968726137 @default.
- W1963621879 cites W1975869151 @default.
- W1963621879 cites W1979081635 @default.
- W1963621879 cites W1991662012 @default.
- W1963621879 cites W2000533117 @default.
- W1963621879 cites W2002497519 @default.
- W1963621879 cites W2008004260 @default.
- W1963621879 cites W2008692148 @default.
- W1963621879 cites W2012088314 @default.
- W1963621879 cites W2025735513 @default.
- W1963621879 cites W2035990797 @default.
- W1963621879 cites W2042078753 @default.
- W1963621879 cites W2048238389 @default.
- W1963621879 cites W2050856282 @default.
- W1963621879 cites W2052085254 @default.
- W1963621879 cites W2069116952 @default.
- W1963621879 cites W2074705578 @default.
- W1963621879 cites W2085773239 @default.
- W1963621879 cites W2085873341 @default.
- W1963621879 cites W2088143209 @default.
- W1963621879 cites W2092280809 @default.
- W1963621879 cites W2093214695 @default.
- W1963621879 cites W2094339929 @default.
- W1963621879 cites W2120954515 @default.
- W1963621879 cites W4246000128 @default.
- W1963621879 doi "https://doi.org/10.1161/01.cir.94.7.1499" @default.
- W1963621879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8840835" @default.
- W1963621879 hasPublicationYear "1996" @default.
- W1963621879 type Work @default.
- W1963621879 sameAs 1963621879 @default.
- W1963621879 citedByCount "48" @default.
- W1963621879 countsByYear W19636218792013 @default.
- W1963621879 countsByYear W19636218792015 @default.
- W1963621879 crossrefType "journal-article" @default.
- W1963621879 hasAuthorship W1963621879A5058141203 @default.
- W1963621879 hasConcept C126322002 @default.
- W1963621879 hasConcept C164705383 @default.
- W1963621879 hasConcept C2778292772 @default.
- W1963621879 hasConcept C2779161974 @default.
- W1963621879 hasConcept C2779215400 @default.
- W1963621879 hasConcept C71924100 @default.
- W1963621879 hasConceptScore W1963621879C126322002 @default.
- W1963621879 hasConceptScore W1963621879C164705383 @default.
- W1963621879 hasConceptScore W1963621879C2778292772 @default.
- W1963621879 hasConceptScore W1963621879C2779161974 @default.
- W1963621879 hasConceptScore W1963621879C2779215400 @default.
- W1963621879 hasConceptScore W1963621879C71924100 @default.
- W1963621879 hasIssue "7" @default.
- W1963621879 hasLocation W19636218791 @default.
- W1963621879 hasLocation W19636218792 @default.
- W1963621879 hasOpenAccess W1963621879 @default.
- W1963621879 hasPrimaryLocation W19636218791 @default.
- W1963621879 hasRelatedWork W1559958385 @default.
- W1963621879 hasRelatedWork W1991134344 @default.
- W1963621879 hasRelatedWork W2023954222 @default.
- W1963621879 hasRelatedWork W2047344647 @default.
- W1963621879 hasRelatedWork W2096338776 @default.
- W1963621879 hasRelatedWork W2352964226 @default.
- W1963621879 hasRelatedWork W2357544290 @default.
- W1963621879 hasRelatedWork W2376011722 @default.
- W1963621879 hasRelatedWork W3029954288 @default.
- W1963621879 hasRelatedWork W4246591656 @default.
- W1963621879 hasVolume "94" @default.
- W1963621879 isParatext "false" @default.
- W1963621879 isRetracted "false" @default.
- W1963621879 magId "1963621879" @default.
- W1963621879 workType "article" @default.